SHUBHAM PANT to Quinolones
This is a "connection" page, showing publications SHUBHAM PANT has written about Quinolones.
Connection Strength
0.316
-
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clin Cancer Res. 2018 07 15; 24(14):3253-3262.
Score: 0.143
-
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov; 78(5):921-927.
Score: 0.129
-
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Invest New Drugs. 2021 08; 39(4):1089-1098.
Score: 0.044